News

CHDI extends its ongoing collaboration for an additional five years through to 2019.

New PRO measure being developed in conjunction with the FNIH Biomarkers Consortium.

Agreement to acquire Kremers Urban Pharmaceuticals from UCB.

P53 considered important biomarker for cancer drug discovery.

Master collaboration agreement is a framework for developing and commercializing QIAGEN companion diagnostics, paired with new or existing products.

In its first clinical application in pediatric patients, an investigational medication developed and manufactured at UC Davis has been found to effectively treat children with life-threatening and difficult-to-control epileptic seizures without side effects, according to a research report by scientists at UC Davis and Northwestern University.

Details of the role of glutamate, the brain's excitatory chemical, in a drug reward pathway have been identified for the first time.

In a pair of related studies, scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified a number of new therapeutic targets for memory disorders and have developed a new screening test to uncover compounds that may one day work against those disorders.

Forget Sudoku: Speaking multiple languages routinely exercises the brain Speaking more than one language is good for the brain, according to new research that indicates bilingual speakers process information more efficiently and more easily than those who know a single language.

Moffitt Cancer Center researchers, in conjunction with colleagues at University of Calgary, have found that the common chemotherapeutic agent cyclophosphamide can help improve the success of oncolytic virus therapy in patients with malignant gliomas, a common type of brain tumor.